Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Pertuzumab | 0.002 | mg/ml | 7447.102 | 0.9593 | 0.9502 | 1.6467 | |||
| HCC1428 | HR+ | Luminal | Pertuzumab | 0.01 | mg/ml | 7441.102 | 0.9598 | 0.9122 | 0.9144 | |||
| BT-20 | TNBC | Basal A | Pertuzumab | 1.25 | mg/ml | 5903.102 | 1.0659 | 1.1043 | 1.2557 | |||
| HCC1569 | HER2amp | Basal A | Pertuzumab | 0.00008 | mg/ml | 7447.102 | 0.9647 | 0.9568 | 1.6467 | |||
| HCC1569 | HER2amp | Basal A | Pertuzumab | 0.01 | mg/ml | 7447.102 | 0.9470 | 0.9350 | 1.6467 | |||
| MCF 10F | NM | - | Pertuzumab | 0.0004 | mg/ml | 7487.102 | 0.9717 | 0.9628 | 1.5273 | |||
| MCF 10F | NM | - | Pertuzumab | 0.002 | mg/ml | 7487.102 | 0.8741 | 0.8313 | 1.5273 |